SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy – EClinicalMedicine
The post SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. appeared first on Links Medicus.
COVID vaccines can block variant hitting Asia, lab study finds – Nature See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress Commentary on Twitter Pfizer & Moderna mRNA vaccines are effective against multiple SARSCoV2 variants, including the B.1.617 & B.1.618, 2 variants underlying the surge in India. The research, while not […]
The post COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”. appeared first on Links Medicus.
AntiCoagulaTIon cOroNavirus – ACTION – American College of Cardiology Commentary: ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 – TCTMD Video: Dr. Renato Lopes and Dr. C. Michael Gibson Discuss: Randomized Clinical Trial To Evaluate A Routine Full Anticoagulation Strategy In Patients With Coronavirus Infection (SARS-CoV-2) Admitted To Hospital: The Coalition ACTION Trial
The post #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding. appeared first on Links Medicus.
Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv Related: [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19 Commentary on Twitter Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced […]
The post [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. appeared first on Links Medicus.
‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT Related: COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization – JAMA Oncology
The post ‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo. appeared first on Links Medicus.
DARE-19: Dapagliflozin in High-Risk Patients Hospitalized With COVID-19 – American College of Cardiology See also: Dapagliflozin in Respiratory Failure in Patients With COVID-19 – DARE-19 – American College of Cardiology Commentaries on Twitter DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile ? Do not discontinue SGLT2i […]
The post #ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19. appeared first on Links Medicus.
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study – The BMJ Commentaries: Expert reaction to study looking at the public health impact of delaying the second dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines – Science Media Centre AND Delaying second Covid vaccine doses can […]
The post Modeling study: Delaying second doses of Pfizer-BioNTech and Moderna mRNA vaccines could reduce deaths by up to 20% under certain conditions. appeared first on Links Medicus.
BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant – The Lancet News release: Delaying second Pfizer vaccines to 12 weeks significantly increases antibody responses in older people, finds study – University of Birmingham Commentaries: Delaying a COVID vaccine’s second dose boosts immune […]
The post [Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age. appeared first on Links Medicus.
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial – The Lancet Invited commentary: Convalescent plasma in patients hospitalised with COVID-19 Commentaries on Twitter Convalescent plasma: Yet another example of Don’t guess, don’t gamble Randomize… and learn I’ve heard it said that it was deemed “too difficult” […]
The post RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19. appeared first on Links Medicus.
Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library Summary: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library
The post Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma. appeared first on Links Medicus.